当前位置:首页>产品中心>单抗/多抗>Anti-Human SLC6A2 NAT1 NET1 SLC6A5 Polyclonal Antibody|抗人SLC6A2/NAT1/NET1/SLC6A5多克隆抗体(靶标:人去甲肾上腺素转运蛋白/甘氨酸转运蛋白)

Anti-Human SLC6A2 NAT1 NET1 SLC6A5 Polyclonal Antibody|抗人SLC6A2/NAT1/NET1/SLC6A5多克隆抗体(靶标:人去甲肾上腺素转运蛋白/甘氨酸转运蛋白)

  • 货号:RB9THD570014
  • 价格:面议
  • 点击:383
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Homo sapiens (Human)
靶标NAT1, NET, NET1, Norepinephrine transporter, SLC6A2, SLC6A5, Sodium-dependent noradrenaline transporter, Solute carrier family 6 member 2
免疫原E. coli - derived recombinant Human SLC6A2 NAT1 NET1 SLC6A5 (Phe167-Pro233&Ser363-Thr402&Pro570-Ile617).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号P23975
背景信息

Sodium-dependent noradrenaline transporter (SLC6A2 NAT1 NET1 SLC6A5) is a ~69 kDa protein. Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signaling neurotransmitter in the autonomic sympathetic nervous system. Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis. Can also mediate sodium- and chloride-dependent transport of dopamine.

1. Pacholczyk, T. et al. (1991) Nature 350, 350-4. PMID: 2008212
2. Gu, H. et al. (1994) The Journal of biological chemistry 269, 7124-30. PMID: 8125921
3. Zhang, H. et al. (2024) Nature 630, 247-254. PMID: 38750358
4. Syringas, M. et al. (2000) Molecular pharmacology 58, 1404-11. PMID: 11093780
5. Brown, CR. et al. (2025) Journal of neurochemistry 169, e16241. PMID: 39395208
6. Tan, J. et al. (2024) Nature 632, 921-929. PMID: 39048818
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Lebrikizumab Non-Neutralizing Recombinant Antibody |抗来瑞珠单抗非中和重组抗体(靶标:来瑞珠单抗非中和抗体) 1007
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 1252
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 925
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 1071
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 1126
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 864
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 843
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 950
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 828
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 713
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 837
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 941
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 830
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 1024
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 895
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 1267
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 1021
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 922
Anti-Sarilumab Non-Neutralizing Recombinant Antibody|抗萨瑞鲁单抗非中和重组抗体(靶标:萨瑞鲁单抗非中和抗体) 1111
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 1021
总计 33036 个记录,共 1652 页,当前第 1646 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30